When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Glucagon-like peptide-1 - Wikipedia

   en.wikipedia.org/wiki/Glucagon-like_peptide-1

   Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption.

3. Cagrilintide/semaglutide - Wikipedia

   en.wikipedia.org/wiki/Cagrilintide/semaglutide

   In December 2024, Novo Nordisk announced the results of REDEFINE 1, one of their series of Phase III trials, testing weekly cagrilintide 2.4 mg and semaglutide 2.4 mg individually and together versus placebo in obese or overweight subjects with one or more comorbidities. [7]

4. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs, or incretin mimetics, [1] are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1, which is released by the gut after eating.

5. Semaglutide - Wikipedia

   en.wikipedia.org/wiki/Semaglutide

   [23] [24] [25] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. [ 26 ] [ 27 ] It can be administered by subcutaneous injection or taken orally . [ 14 ] [ 15 ] [ 16 ] [ 28 ] It is sold by Novo Nordisk under the brand names Ozempic [ 14 ] and Rybelsus [ 15 ] for diabetes, and under the brand name ...

6. Largest-ever Ozempic and GLP-1 drug study finds they lower ...

   www.aol.com/finance/largest-ever-ozempic-glp-1...

   As the GLP-1 patients in Al-Aly’s study were all veterans, with full drug coverage, their retention rate was higher—roughly 70% after a year. How the study’s results will be interpreted or ...

7. GLP1 poly-agonist peptides - Wikipedia

   en.wikipedia.org/wiki/GLP1_poly-agonist_peptides

   GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.